Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $10.19, for a total transaction of $76,425.00. Following the transaction, the insider now directly owns 132,736 shares of the company’s stock, valued at $1,352,579.84. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of Edge Therapeutics, Inc. (NASDAQ EDGE) traded down 0.20% on Monday, hitting $10.11. 24,888 shares of the stock were exchanged. Edge Therapeutics, Inc. has a one year low of $7.30 and a one year high of $13.50. The firm’s 50-day moving average is $10.07 and its 200-day moving average is $10.13. The company’s market cap is $311.50 million.
Edge Therapeutics (NASDAQ:EDGE) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.42) EPS for the quarter, hitting analysts’ consensus estimates of ($0.42). On average, equities analysts forecast that Edge Therapeutics, Inc. will post ($1.81) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/markets/2285599/brian-a-leuthner-sells-7500-shares-of-edge-therapeutics-inc-edge-stock.html.
Hedge funds have recently added to or reduced their stakes in the company. Regentatlantic Capital LLC acquired a new stake in Edge Therapeutics during the first quarter worth approximately $1,230,000. Eagle Asset Management Inc. increased its stake in Edge Therapeutics by 4.4% in the first quarter. Eagle Asset Management Inc. now owns 899,968 shares of the biotechnology company’s stock worth $8,198,000 after buying an additional 37,536 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Edge Therapeutics during the first quarter worth approximately $297,000. TFS Capital LLC acquired a new stake in Edge Therapeutics during the first quarter worth approximately $209,000. Finally, Vanguard Group Inc. increased its stake in Edge Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock worth $6,377,000 after buying an additional 19,973 shares during the last quarter. Institutional investors and hedge funds own 48.72% of the company’s stock.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285599/brian-a-leuthner-sells-7500-shares-of-edge-therapeutics-inc-edge-stock.html
Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.